Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET
The Massachusetts General Hospital Radiochemistry Program, in collaboration with Pfizer, has developed unique 11 C and 18 F-labeling strategies to synthesize isotopologs of lorlatinib (PF-06463922) which is undergoing phase III clinical trial investigations for treatment of non-small-cell lung cance...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publications
2017-10-01
|
| Series: | Molecular Imaging |
| Online Access: | https://doi.org/10.1177/1536012117736669 |